Status: Recruiting
CB-103 With Either Lenvatinib or Abemaciclib in Patients With NOTCH ACC
The goal of this study is to treat patients with NOTCH active advanced adenoid cystic carcinoma (ACC) tumors with a combination or two different oral medications to slow tumor growth and improve survival outcomes. The names of the study drugs involved in this study are: * CB-103 (an oral NOTCH pathway inhibitor) * Abemaciclib (CDK4/6 inhibitor) * Lenvatinib (a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI))
Participants needed: 32
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Michael J. Dennis, MDUpdated: Sep 9, 2026Locations: 1
Eligibility criteria
Participants must have histologically confirmed adenoid cystic carcinoma (ACC) w... [+13]
Participant has untreated or clinically symptomatic CNS metastases and/or carcin... [+8]